Next Article in Journal
Combined Cancer Patient–Reported Symptom and Health Utility Tool for Routine Clinical Implementation: A Real-World Comparison of the ESAS and EQ-5D in Multiple Cancer Sites
Previous Article in Journal
Breast Cancer Screening Policy—Good Science Should Trump Bad Politics
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Inter-Laboratory Proficiency Testing Scheme for Tumour Next-Generation Sequencing in Ontario: A Pilot Study

1
Advanced Molecular Diagnostics Laboratory, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
2
Bioinformatics and HPC Core, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
3
Cancer Genomics Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
4
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
5
Department of Medicine, University of Toronto, Toronto, ON, Canada
6
Department of Clinical Laboratory Genetics, University Health Network, Toronto, ON, Canada
7
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
8
Molecular Diagnostics, Kingston Health Sciences Centre, Kingston, ON, Canada
9
Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON, Canada
10
Molecular Oncology Diagnostics Laboratory, The Ottawa Hospital, Ottawa, ON, Canada
11
Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, ON, Canada
12
Hamilton Health Sciences and St. Joseph’s Healthcare, Hamilton, ON, Canada
13
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
14
Pathology and Laboratory Medicine Program, London Health Sciences Centre, London, ON, Canada
15
Department of Pathology and Laboratory Medicine, Western University, London, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(6), 717-732; https://doi.org/10.3747/co.26.5379
Submission received: 13 September 2019 / Revised: 7 October 2019 / Accepted: 3 November 2019 / Published: 1 December 2019

Abstract

Background: A pilot inter-laboratory proficiency scheme for 5 Ontario clinical laboratories testing tumour samples for the Ontario-wide Cancer Targeted Nucleic Acid Evaluation (OCTANE) study was undertaken to assess proficiency in the identification and reporting of next-generation sequencing (NGS) test results in solid tumour testing from archival formalin-fixed, paraffin-embedded (FFPE) tissue. Methods: One laboratory served as the reference centre and provided samples to 4 participating laboratories. An analyte-based approach was applied: each participating laboratory received 10 FFPE tissue specimens profiled at the reference centre, with tumour site and histology provided. Laboratories performed testing per their standard NGS tumour test protocols. Items returned for assessment included genes and variants that would be typically reported in routine clinical testing and variant call format (VCF) files to allow for assessment of NGS technical quality. Results: Two main aspects were assessed: (1) Technical quality and accuracy of identification of exonic variants; (2) Site-specific reporting practices. Technical assessment included evaluation of exonic variant identification, quality assessment of the VCF files to evaluate base calling, variant allele frequency, and depth of coverage for all exonic variants. Concordance at 100% was observed from all sites in the technical identification of 98 exonic variants across the 10 cases. Variability between laboratories in the choice of variants considered clinically reportable was significant. Of the 38 variants reported as clinically relevant by at least 1 site, only 3 variants were concordantly reported by all participating centres as clinically relevant. Conclusions: Although excellent technical concordance for ngs tumour profiling was observed across participating institutions, differences in the reporting of clinically relevant variants were observed, highlighting reporting as a gap where consensus on the part of Ontario laboratories is needed.
Keywords: external quality assessment; inter-laboratory comparison; next-generation sequencing; tumour molecular profiling external quality assessment; inter-laboratory comparison; next-generation sequencing; tumour molecular profiling

Share and Cite

MDPI and ACS Style

Spence, T.; Stickle, N.; Yu, C.; Chow, H.; Feilotter, H.; Lo, B.; McCready, E.; Sadikovic, B.; Siu, L.L.; Bedard, P.L.; et al. Inter-Laboratory Proficiency Testing Scheme for Tumour Next-Generation Sequencing in Ontario: A Pilot Study. Curr. Oncol. 2019, 26, 717-732. https://doi.org/10.3747/co.26.5379

AMA Style

Spence T, Stickle N, Yu C, Chow H, Feilotter H, Lo B, McCready E, Sadikovic B, Siu LL, Bedard PL, et al. Inter-Laboratory Proficiency Testing Scheme for Tumour Next-Generation Sequencing in Ontario: A Pilot Study. Current Oncology. 2019; 26(6):717-732. https://doi.org/10.3747/co.26.5379

Chicago/Turabian Style

Spence, T., N. Stickle, C. Yu, H. Chow, H. Feilotter, B. Lo, E. McCready, B. Sadikovic, L. L. Siu, P. L. Bedard, and et al. 2019. "Inter-Laboratory Proficiency Testing Scheme for Tumour Next-Generation Sequencing in Ontario: A Pilot Study" Current Oncology 26, no. 6: 717-732. https://doi.org/10.3747/co.26.5379

APA Style

Spence, T., Stickle, N., Yu, C., Chow, H., Feilotter, H., Lo, B., McCready, E., Sadikovic, B., Siu, L. L., Bedard, P. L., & Stockley, T. L. (2019). Inter-Laboratory Proficiency Testing Scheme for Tumour Next-Generation Sequencing in Ontario: A Pilot Study. Current Oncology, 26(6), 717-732. https://doi.org/10.3747/co.26.5379

Article Metrics

Back to TopTop